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Background
The glycerophospholipid Phosphatidic acid (PA) has
been identified as a potential nutritional treatment for
gastrointestinal disorders. Dietary food sources rich in
PA include cabbage and radish leaves as well as Mallotus
japonicas, a Japanese edible herb historically used for the
treatment of stomach ulcers. The mammalian target of
rapamycin (mTOR) has been shown to regulate rates of
muscle protein synthesis and a mechanical stimulus (resis-
tance exercise) has been shown to activate mTOR with
PA playing a key role. Supplementation with soy-derived
PA significantly increases responses in skeletal muscle
hypertrophy, lean body mass, and maximal strength to
resistance exercise. PA accounts for less than 0.1% of the
total glycerophospholipid concentration of 201 mg/dl in
the human plasma. 15 of the more than 600 distinct mole-
cular lipid species quantified in human plasma are PA,
6 are lysophosphatidic acid (LPA). Orally administered PA
can be metabolized to LPA and glycerophosphate by
pancreatic phospholipases A1 and A2, which hydrolyze
the fatty acid at the sn-1 position and the sn-2 position,
respectively. Lysophospholipids are absorbed by the muco-
sal cells of the gastrointestinal tract and are rapidly
re-acylated with fatty acids of the body pool resulting in a
newly-formed phospholipid-molecule whose fatty acid
composition is determined by the physiological and nutri-
tional status and not by its source. This study sought to
assess the effect of soy-derived PA supplementation on
concentrations LPA and PA molecular species in human
plasma.
Methods
After a 12 hour overnight fast one subject (20 years of
age, bodyweight of 82 kg, and height of 178 cm) was
assigned to receive 1.5 grams of soy-derived PA (Mediator,
Chemi Nutra, White Bear Lake, MN). Blood draws were
taken immediately prior to, and at 30 min, 1, 2, 3, and
7 hours following supplementation. The samples were
analyzed by an ultra-performance liquid chromatograph
with triple quadrupole mass spectrometry (LC/MS/MS)
using 17:1-LPA and 37:4-PA as internal standards to
determine the concentration of LPA and PA molecular
species in human plasma.
Results
At baseline, 19 PA (highest concentrations: C34:2 (15%),
C40:4 (11%), and C36:4 (10%)) and 5 LPA (16:0 (45%),
18:2 (19%), 20:4 (17%), 14:0 (11%) and 18:1 (8%)) mole-
cular species could be quantified with total concentra-
tions of PA of 2.66 nmol/ml, and LPA of 0.11 nmol/ml.
Plasma concentrations of PA peaked at 3 hours (+32%)
after ingestion and stayed elevated even after 7 hours
(+18%). LPA showed a bimodal absorption kinetic with
peaks after 1 hour (+500%) and 3 hours (+264%), after
almost dropping back to baseline levels after 2 hours.
On an individual fatty acid level, most prominent was a
23-fold increase in 20:4-LPA after 1 hour compared to
baseline. The increase in 20:4-LPA does not result from
the administration of PA, since soy-derived PA does not
contain any arachidonic acid (fatty acids distribution of
soy-PA: 18:2 (66.1%), 18:1 (12.6%), 16:0 (11.7%), 18:3
(6.1%) and 18:0 (3.4%)). Absorption of soy-derived PA
must yield glycerophosphate which is re-acylated with
arachidonic acid.
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Conclusion
LPA and PA can be molecularly identified and measured.
LPA, PA and LPA+PA plasma levels increase 30 min after
ingestions, plateau at 1-3 hours and remain above baseline
levels after 7 hours. This is the first case study showing
that orally administered PA is bioavailable. Future research
should repeat this case study with a larger n-size and
include the analysis of omega 3 fatty acid-LPA molecular
species.
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